Birdwatch Archive

Birdwatch Note

2024-02-27 15:21:19 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

The product marketed here is not Ozempic or Wegovy, the semaglutide drug prescribed for weight loss, or Rybelsus, the semaglutide oral pill, but Naltrexone/bupropion (aka Wellbutrin), a fixed dose weight loss drug that combines an opioid antagonist with a an antidepressant. https://www.hims.com/shop/wl-start-hims-gen?utm_source=google&utm_medium=pla&utm_campaign=20819085785&utm_term=--&utm_content=&mt=&utm_platform=m&utm_product=nb_demeter&gad_source=1&gclid=CjwKCAiArfauBhApEiwAeoB7qEX_WgsKQUmFJ86TjbXCJDAIremyH1mmSWsMLnhOi1CGD0frTwLrvhoC9ooQAvD_BwE https://medlineplus.gov/druginfo/meds/a619020.html

Written by 823CEF8138FF728618506CFEED5A3FF25A19BD2CF7107C337CEE2890CE5D3AD7
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1762252448842801303

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1762498152551055769
  • noteId - 1762498152551055769
  • participantId -
  • noteAuthorParticipantId - 823CEF8138FF728618506CFEED5A3FF25A19BD2CF7107C337CEE2890CE5D3AD7 Participant Details
  • createdAtMillis - 1709047279856
  • tweetId - 1762252448842801303
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 1
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • The product marketed here is not Ozempic or Wegovy, the semaglutide drug prescribed for weight loss, or Rybelsus, the semaglutide oral pill, but Naltrexone/bupropion (aka Wellbutrin), a fixed dose weight loss drug that combines an opioid antagonist with a an antidepressant. https://www.hims.com/shop/wl-start-hims-gen?utm_source=google&utm_medium=pla&utm_campaign=20819085785&utm_term=--&utm_content=&mt=&utm_platform=m&utm_product=nb_demeter&gad_source=1&gclid=CjwKCAiArfauBhApEiwAeoB7qEX_WgsKQUmFJ86TjbXCJDAIremyH1mmSWsMLnhOi1CGD0frTwLrvhoC9ooQAvD_BwE https://medlineplus.gov/druginfo/meds/a619020.html

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2024-02-27 15:21:19 UTC
(1709047279856)
2024-02-28 00:19:09 UTC
(1709079549924)
CURRENTLY_RATED_NOT_HELPFUL 2024-03-07 12:28:42 UTC
(1709814522945)
NEEDS_MORE_RATINGS 2024-02-28 00:19:09 UTC
(1709079549924)
CURRENTLY_RATED_NOT_HELPFUL

Note Ratings

rated at rated by
2024-02-27 15:17:52 -0600 Rating Details
2024-02-27 15:14:59 -0600 Rating Details
2024-02-27 14:11:33 -0600 Rating Details
2024-02-27 12:50:49 -0600 Rating Details
2024-02-27 11:52:13 -0600 Rating Details
2024-02-27 11:42:03 -0600 Rating Details
2024-02-27 11:39:48 -0600 Rating Details
2024-02-27 11:36:01 -0600 Rating Details
2024-02-27 10:16:03 -0600 Rating Details
2024-02-27 09:41:40 -0600 Rating Details
2024-02-27 09:37:28 -0600 Rating Details
2024-02-27 15:21:36 -0600 Rating Details
2024-02-27 14:37:38 -0600 Rating Details
2024-02-27 13:36:47 -0600 Rating Details
2024-02-27 11:10:18 -0600 Rating Details
2024-02-27 11:02:55 -0600 Rating Details
2024-02-27 10:47:02 -0600 Rating Details
2024-02-27 10:13:39 -0600 Rating Details
2024-02-27 19:25:37 -0600 Rating Details
2024-02-27 17:55:16 -0600 Rating Details
2024-02-27 17:21:40 -0600 Rating Details
2024-02-27 17:10:30 -0600 Rating Details
2024-02-27 16:32:43 -0600 Rating Details
2024-02-27 16:30:09 -0600 Rating Details
2024-02-27 16:08:39 -0600 Rating Details
2024-02-27 15:05:51 -0600 Rating Details
2024-02-27 13:36:01 -0600 Rating Details
2024-02-27 12:59:19 -0600 Rating Details
2024-02-27 11:47:31 -0600 Rating Details
2024-02-27 11:22:07 -0600 Rating Details
2024-02-27 11:06:16 -0600 Rating Details
2024-02-27 10:27:56 -0600 Rating Details
2024-02-27 10:19:56 -0600 Rating Details
2024-02-27 10:01:47 -0600 Rating Details
2024-02-27 09:32:51 -0600 Rating Details
2024-02-27 09:28:39 -0600 Rating Details
2024-03-26 20:42:02 -0500 Rating Details